Compare Global X CleanTech (CTEC) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X CleanTech vs Neurocrine Biosciences Inc — how do they compare? Global X CleanTech trades at $55.45 (market cap $25.33M), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Neurocrine Biosciences Inc is far larger — about 576.4× Global X CleanTech's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Global X CleanTech nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X CleanTech for 42 Days and Neurocrine Biosciences Inc for 23 Days on average.
| CTEC | NBIX | |
|---|---|---|
Market Cap | $25.33M | $14.60B |
Volume | 2,662 | 1,075,694 |
Sector | Sector/Thematic | Health |
52-Week High | $78.11 | $185.50 |
52-Week Low | $50.82 | $123.10 |
Typical Hold Time | 42 Days | 23 Days |
Enterprise Value | — | $14.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X CleanTech
CTEC invests in companies at the forefront of the clean technology industry. It focuses on disruptive innovations in renewable energy production, energy storage, smart grids, and energy efficiency, with top holdings like Enphase and First Solar.
Read more on CTEC →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
